Jennifer Friedmann

Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma

Rahima Jamal, Réjean Lapointe, Eftihia Cocolakis et al. · Journal for ImmunoTherapy of Cancer · 2017 · 53 citations · Full text

The Impact of COVID-19 on the Diagnosis and Treatment of Lung Cancer at a Canadian Academic Center: A Retrospective Chart Review

Goulnar Kasymjanova, Aksa Anwar, Victor Cohen et al. · Current Oncology · 2021 · 52 citations · Full text

Surgical Oncology, Cancer Management, Cancer Registration +23

A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group

Glenwood Goss, Hal W. Hirte, Wilson H. Miller et al. · Investigational New Drugs · 2005 · 47 citations

National Cancer Institute, Oncology, Oral Potentially Malignant Disorders +9

The Cytoplasmic Domain of Igα Is Necessary and Sufficient to Support Efficient Early B Cell Development

Kelly A. Pike, Sandra Iacampo, Jennifer Friedmann et al. · The Journal of Immunology · 2004 · 32 citations · Full text

Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden

Michael Schenker, Mauricio Burotto, Martin Eduardo Richardet et al. · Journal for ImmunoTherapy of Cancer · 2024 · 32 citations · Full text